Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 12:2023:8825358.
doi: 10.1155/2023/8825358. eCollection 2023.

Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Affiliations
Review

Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Kuldeep Singh et al. Behav Neurol. .

Abstract

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease, which present major healthcare concerns on a worldwide scale. Despite the lack of available therapies, CBD has been shown to possess a variety of pharmacological effects in preclinical and clinical studies, making it an intriguing competitor. This review brings together the most recent findings on the endocannabinoid and neurotransmitter systems, as well as anti-inflammatory pathways, that underlie CBD's modes of action. Synthesized efficacy and safety assessments for a range of neurological illnesses are included, covering human trials, in vitro studies, and animal models. The investigation includes how CBD could protect neurons, control neuroinflammation, fend off oxidative stress, and manage neuronal excitability. This study emphasizes existing clinical studies and future possibilities in CBD research, addressing research issues such as regulatory complications and contradicting results, and advocates for further investigation of therapeutic efficacy and ideal dose methodologies. By emphasizing CBD's potential to improve patient well-being, this investigation presents a revised viewpoint on its suitability as a therapeutic intervention for neurological illnesses.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structure of cannabidiol.

References

    1. Micale V., Di Marzo V., Sulcova A., Wotjak C. T., Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacology & Therapeutics . 2013;138(1):18–37. doi: 10.1016/j.pharmthera.2012.12.002. - DOI - PubMed
    1. Borsook D. Neurological diseases and pain. Brain . 2012;135(2):320–344. doi: 10.1093/brain/awr271. - DOI - PMC - PubMed
    1. National Academies of Sciences E and M. Therapeutic effects of cannabis and cannabinoids . 2017. June 2023, https://www.ncbi.nlm.nih.gov/books/NBK425767/
    1. Kucerova J., Tabiova K., Drago F., Micale V. Therapeutic potential of cannabinoids in schizophrenia. Recent Patents on CNS Drug Discovery . 2014;9(1):13–25. doi: 10.2174/1574889809666140307115532. - DOI - PubMed
    1. de Morais H., de Souza C. P., da Silva L. M., et al. Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: role of CB1 receptors. European Neuropsychopharmacology . 2016;26(10):1590–1600. doi: 10.1016/j.euroneuro.2016.08.007. - DOI - PubMed